[Outlook and experience in using ofloxacin in urology].
Ofloxacin was used in the empirical and etiotropic therapy of patients with severe urinary tract infection. The trial was based on the previous experience with ofloxacin in the treatment of various forms of urological infection with determination of the pathogen susceptibility and study of the drug pharmacokinetics in patients with normal and impaired renal function. For the first 3 to 5 days in the present study ofloxacin was administered in a dose of 200 mg twice a day followed by its oral use in the same dosage for 3 to 5 days. The treatment schemes were corrected by the bacteriological findings (mainly when Pseudomonas aeruginosa strains were isolated). The results of the treatment of more than 200 patients showed that ofloxacin was highly efficient. By the clinical and bacteriological indices the drug proved to be efficient in 96 and 88 per cent of the cases respectively. In the treatment of patients with noncomplicated urinary tract infection good results (the clinical and bacteriological efficacies of 96 and 88 per cent respectively) were observed when ofloxacin was used orally in a single dose of not more than 400 mg once a day for 3 to 5 days. In the patients with chlamydiosis the drug was used in the same dosage for 10 days. Ofloxacin was also shown to be highly efficient when used prophylactically in transurethral surgical operations on the prostate and in open urological operations.
Derevianko
I I
II
Kotliarova
G A
GA
Siniukhin
V N
VN
D000284:Administration, Oral; D000892:Anti-Infective Agents, Urinary / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005544:Forecasting; D006090:Gram-Negative Bacteria / Q000187:drug effects; D006094:Gram-Positive Bacteria / Q000187:drug effects; D006801:Humans; D007262:Infusions, Intravenous; D007669:Kidney Calculi / Q000188:drug therapy; D008826:Microbial Sensitivity Tests; D015242:Ofloxacin / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011704:Pyelonephritis / Q000188:drug therapy; D016896:Treatment Outcome; D014570:Urologic Diseases / Q000188:drug therapy*; D014572:Urology / Q000639:trends*
D000892:Anti-Infective Agents, Urinary; D015242:Ofloxacin